Supernus Pharmaceuticals, Inc. (SUPN) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) released its earnings results on Monday. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.02, Briefing.com reports. The business had revenue of $80.40 million for the quarter, compared to analyst estimates of $78.74 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. The company’s revenue was up 41.5% on a year-over-year basis.
Supernus Pharmaceuticals (NASDAQ SUPN) traded down $4.60 during midday trading on Tuesday, reaching $36.50. 241,859 shares of the company’s stock traded hands, compared to its average volume of 435,823. Supernus Pharmaceuticals has a fifty-two week low of $18.25 and a fifty-two week high of $50.04. The company has a quick ratio of 1.74, a current ratio of 1.94 and a debt-to-equity ratio of 0.01. The stock has a market cap of $1,850.00, a PE ratio of 36.89, a PEG ratio of 1.84 and a beta of 1.30.
In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 3,709 shares of the firm’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $45.23, for a total value of $167,758.07. Following the sale, the vice president now owns 17,500 shares of the company’s stock, valued at approximately $791,525. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Stefan K.F. Schwabe sold 95,000 shares of the firm’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $46.59, for a total transaction of $4,426,050.00. The disclosure for this sale can be found here. Insiders sold a total of 153,709 shares of company stock worth $7,223,108 over the last quarter. Corporate insiders own 6.70% of the company’s stock.
Several equities research analysts have recently commented on SUPN shares. Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. FBR & Co started coverage on shares of Supernus Pharmaceuticals in a research report on Thursday, October 19th. They issued a “buy” rating and a $53.00 price objective for the company. Piper Jaffray Companies reissued a “hold” rating and set a $45.00 target price on shares of Supernus Pharmaceuticals in a research report on Friday, September 8th. Stifel Nicolaus reissued a “buy” rating and set a $47.00 target price (up from $36.00) on shares of Supernus Pharmaceuticals in a research report on Tuesday, July 18th. Finally, Janney Montgomery Scott started coverage on shares of Supernus Pharmaceuticals in a research report on Friday, July 14th. They set a “neutral” rating and a $47.00 target price for the company. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $49.78.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.